Telomir Pharmaceuticals reported on November 20, 2025, that their compound Telomir-1 effectively kills aggressive human leukemia (HL60) cells, showing a dose-dependent reduction in cell viability. This expands its potential use in treating various cancers, reinforcing the company's ongoing oncology research efforts.